Legend Biotech (LEGN) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
15 Nov, 2026CARVYKTI commercial scale and market opportunity
Q2 2026 net trade sales reached $657M, up 50% YoY; FY25 net trade sales were $1.9B, and the franchise became profitable in 2025.
More than 10,000 patients had been treated worldwide; manufacturing success was 99% and median U.S. turnaround time was 29 days in Q1 2026.
339 global treatment sites and 151 U.S. sites were active as of June 30, 2026; annualized dose capacity was 10,000 in 2026.
In 2025, ≤5% of U.S. patients treated in 2L–4L received a BCMA-targeting agent, while ≤10% in 5L+ received CAR-T, indicating room for earlier-line adoption.
Priorities include sequential sales growth, broader globalization, and having three-quarters of CARVYKTI orders come from 2L–4L.
Clinical evidence and earlier-line expansion
In CARTITUDE-2 Cohort A (1–3 prior lines; N=20), 5-year PFS was 54.2% and OS was 69.2%, versus 33.7% and 51.3% in CARTITUDE-1 (≥3 prior lines; N=97).
Median PFS was 34.9 months in CARTITUDE-1, 50.4 months in a combined CARTITUDE-1/4 analysis, and not reached in CARTITUDE-4 at 34 months’ median follow-up.
CARTITUDE-5 and CARTITUDE-6 are registrational frontline studies; CARTITUDE-5 enrollment is complete, while CARTITUDE-6 compares cilta-cel with ASCT in transplant-eligible newly diagnosed patients.
Updated management strategies were associated with parkinsonism rates declining from 6% in CARTITUDE-1 to 1% in CARTITUDE-4; 95% of reported cases in a 761-patient analysis occurred among patients who did not respond to bridging therapy.
The presentation cites NCCN Category 1 status after one prior therapy and recommends considering CAR-T before bispecific T-cell engagers for eligible patients.
Pipeline and cell therapy innovation
The pipeline spans autologous, allogeneic, and in vivo programs targeting blood cancers, solid tumors, and autoimmune diseases; LB2501 is an in vivo CD19×CD20 CAR-T candidate for B-cell NHL.
In LB2501 dose level 2, ORR was 100% (6/6) and CR was 83.3% (5/6); median follow-up was 2.3 months, all responses were ongoing at the April 1 cutoff, and no DLTs, SAEs, or deaths were reported.
A U.S. IND filing for LB2501 was anticipated in 2H 2026; multiple U.S. IND-enabling studies are planned for oncology indications.
Development strategy uses China investigator-initiated trials to establish early proof of concept before larger global studies; the in vivo platform moved from candidate selection to first patient dosed in ~6 months.
2026 business development priorities include strategic partnerships for non-dilutive funding, new revenue beyond CARVYKTI, and growth in core cell and gene therapies and enabling technologies.
Latest events from Legend Biotech
- CARVYKTI sales rose 36%; FY26 adjusted profitability remains the target.LEGN
Q3 2026 - CARVYKTIⓇ sales up 50% year-over-year, driving profitability and strong cash position.LEGN
Q2 2026 - Cilta-cel delivers strong survival gains and safer, more convenient treatment for myeloma patients.LEGN
The 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024 - Earlier CARVYKTI use improves survival, safety, and access in multiple myeloma.LEGN
American Society of Clinical Oncology (ASCO) Annual Meeting 2026 - CARVYKTIⓇ sales jumped 62% year-over-year, fueling revenue growth and margin improvement.LEGN
Q1 2026 - Q4 2025 CARVYKTI sales surged 66% YoY, driving profitability and global expansion.LEGN
Q4 2025 - Carvykti's growth accelerates with expanded capacity, strong efficacy, and promising pipeline advances.LEGN
Morgan Stanley 22nd Annual Global Healthcare Conference - CARVYKTI sales soared 135% year-over-year, fueling revenue growth and global expansion.LEGN
Q1 2025 - 2024 revenue surged and net loss narrowed, with CARVYKTI driving growth and strong cash reserves.LEGN
Q4 2024